Qube Research & Technologies (QRT)
MTNB icon

Qube Research & Technologies (QRT)’s Matinas BioPharma MTNB Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,190
Closed -$60K – 2800
2021
Q4 		$60K Buy
+1,190
New +$63.6K ﹤0.01% 2228
2021
Q2 		– Sell
-446
Closed -$23K – 2623
2021
Q1 		$23K Sell
446
-783
-64% -$52.5K ﹤0.01% 1815
2020
Q4 		$84K Buy
+1,229
New +$56.9K ﹤0.01% 1663

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Qube Research & Technologies (QRT)'s MTNB Position: Q1 2022 in Review

Qube Research & Technologies (QRT) sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 1,190 shares — an estimated $60K sold.

Qube Research & Technologies (QRT) first reported a position in MTNB in Q4 2020 and held it in 3 quarters. The position peaked at $84K in Q4 2020. 56 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

  • Qube Research & Technologies (QRT) reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 1,190 Matinas BioPharma shares in Q1 2022, an estimated $60K.
  • Qube Research & Technologies (QRT) first reported a position in Matinas BioPharma in Q4 2020 and held it in 3 quarters.
  • Qube Research & Technologies (QRT)'s Matinas BioPharma position peaked at $84K in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2022, filed 9 May 2022.